{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Class:
PROTEIN
Ilatreotide was developed as a somatostatin receptor agonist with potential for treating gastroenteropancreatic tumors. It is an orally active pituitary and guts hormonal secretion inhibitor.
Status:
Designated
Source:
FDA ORPHAN DRUG:782420
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Xigris
(2001)
Source URL:
First approved in 2001
Source:
Xigris
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00370877: Phase 4 Interventional Completed Postpartum Hemorrhage
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:soficabtagene geleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:persicabtagene lemgedleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
